AbbVie (ABBV)
(Delayed Data from NYSE)
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $197.40 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $197.40 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Novartis Resubmits BLA to FDA for Biosimilar of Neulasta
by Zacks Equity Research
Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.
Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
by Zacks Equity Research
Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $80.76 in the latest trading session, marking a +0.2% move from the prior day.
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals
by Zacks Equity Research
AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.
Gilead & Galapagos Announce Positive Data on Arthritis Drug
by Zacks Equity Research
Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.
AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan
by Zacks Equity Research
AbbVie's (ABBV) psoriasis drug Skyrizi gains the maiden approval in Japan for treating adults with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $79.64, moving -0.15% from the previous trading session.
This is Why AbbVie (ABBV) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA
by Zacks Equity Research
FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $80.65 in the latest trading session, marking a -0.85% move from the prior day.
Roche Receives EC Approval for Label Expansion of Hemlibra
by Zacks Equity Research
Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.
Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study
by Zacks Equity Research
Theravance (TBPH) commences phase IIb/III study for its gut-selective pan- JAK inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis.
Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval
by Zacks Equity Research
FDA approves Pfizer's (PFE) biosimilar version Roche's (RHHBY) breast cancer drug, Herceptin.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $78.08, marking a +0.64% move from the previous day.
Should Value Investors Consider Abbvie (ABBV) Stock Now?
by Zacks Equity Research
Let's see if Abbvie (ABBV) stock is a good choice for value-oriented investors right now from multiple angles.
Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs
by Zacks Equity Research
J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.
Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC
by Zacks Equity Research
Roche (RHHBY) obtains approval for the label expansion of Tecentriq in Europe. The company also submits its sNDA for leukemia drug, Venclexta.
Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed
by Zacks Equity Research
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.
Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
The Zacks Analyst Blog Highlights: Intel, AbbVie, United Technologies, Simon Property and FirstEnergy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, AbbVie, United Technologies, Simon Property and FirstEnergy
AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab
by Zacks Equity Research
AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.
Top Research Reports for Intel, AbbVie & United Technologies
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), AbbVie (ABBV) and United Technologies (UTX).
Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices
by Zacks Equity Research
Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.
Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Momenta (MNTA) reported a narrower loss in Q4, while sales came ahead of expectations.
The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie